Here are the four latest drugs or medical devices approved by the Food and Drug Administration in the past week.
- Kalydeco may now be used to treat patients with 33 genetic mutations associated with cystic fibrosis. The FDA originally approved the drug to treat 10 disease mutations.
- MindMotion Pro is a neuro-technology platform that uses virtual reality to aid in stroke patients' rehabilitation.
- Clofarabine is intended to treat pediatric patients 21 years and younger with acute lymphoblastic leukemia who've previously received at least two other treatments.
- Levocetirizine dihydrochloride is a generic treatment used to relieve symptoms associated with perennial allergic rhinitis in children two years old and younger.